IN2014DN08562A - - Google Patents

Info

Publication number
IN2014DN08562A
IN2014DN08562A IN8562DEN2014A IN2014DN08562A IN 2014DN08562 A IN2014DN08562 A IN 2014DN08562A IN 8562DEN2014 A IN8562DEN2014 A IN 8562DEN2014A IN 2014DN08562 A IN2014DN08562 A IN 2014DN08562A
Authority
IN
India
Prior art keywords
sert
prodrugs
pharmaceutically acceptable
acceptable salt
pharmaceutical compositions
Prior art date
Application number
Inventor
Sharon Mates
Robert Davis
Peng Li
Lawrence Wennogle
Richard A Lerner
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of IN2014DN08562A publication Critical patent/IN2014DN08562A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to particular substituted heterocycle fused gamma carbolines their prodrugs in free solid pharmaceutically acceptable salt and/or substantially pure form as described herein pharmaceutical compositions thereof and methods of use in the treatment of diseases involving 5 HT2A receptor serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems..
IN8562DEN2014 2012-04-14 2013-04-14 IN2014DN08562A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261624292P 2012-04-14 2012-04-14
US201261624291P 2012-04-14 2012-04-14
US201261624293P 2012-04-14 2012-04-14
US201261671723P 2012-07-14 2012-07-14
US201261671713P 2012-07-14 2012-07-14
PCT/US2013/036514 WO2013155505A1 (en) 2012-04-14 2013-04-14 Organic compounds

Publications (1)

Publication Number Publication Date
IN2014DN08562A true IN2014DN08562A (en) 2015-05-22

Family

ID=49328233

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8562DEN2014 IN2014DN08562A (en) 2012-04-14 2013-04-14

Country Status (12)

Country Link
US (8) US20150080404A1 (en)
EP (4) EP2836213B1 (en)
JP (6) JP6242855B2 (en)
KR (1) KR20140146192A (en)
CN (1) CN104519886B (en)
AU (1) AU2013245702A1 (en)
CA (1) CA2870303A1 (en)
ES (1) ES2727815T3 (en)
IN (1) IN2014DN08562A (en)
MX (1) MX2014012374A (en)
RU (1) RU2014145682A (en)
WO (3) WO2013155504A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102065319B1 (en) 2007-03-12 2020-01-10 인트라-셀룰라 써래피스, 인코퍼레이티드. Substituted heterocycle fused gamma-carbolines synthesis
MX347257B (en) 2008-03-12 2017-04-20 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines solid.
CN102105059B (en) 2008-05-27 2015-09-30 细胞内治疗公司 Methods and compositions for sleep disorders and other disorders
KR101868165B1 (en) 2010-04-22 2018-07-19 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2013155504A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel methods
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
CN105939712A (en) * 2013-12-03 2016-09-14 细胞内治疗公司 new method
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
KR20170012210A (en) * 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
CN104003987B (en) * 2014-06-03 2016-03-23 中国药科大学 Tacrine-β-carboline isobicons multifunctional cholinesterase inhibitors
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
US20170007618A1 (en) * 2015-06-17 2017-01-12 Massachusetts Institute Of Technology Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders
KR20240170975A (en) 2016-01-26 2024-12-05 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
ES2879888T3 (en) * 2016-03-25 2021-11-23 Intra Cellular Therapies Inc Organic compounds and their use in the treatment or prevention of disorders of the central nervous system
EP3436455A4 (en) 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
EP3436083A4 (en) * 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
US11433253B2 (en) 2017-02-15 2022-09-06 The Regents Of The University Of California Light therapy system and methods of use
JP7458786B2 (en) * 2017-02-15 2024-04-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Improved phototherapy systems and methods of use
IL268970B2 (en) 2017-03-24 2023-12-01 Intra Cellular Therapies Inc Oral transmucosal formulations of substituted heterocycle fused gamma carbolines
JP2020513023A (en) 2017-04-10 2020-04-30 ドクター・レディーズ・ラボラトリーズ・リミテッド Amorphous Form and Solid Dispersion of Lumateperone p-Tosylate
CN111093664B (en) * 2017-07-26 2023-06-02 细胞内治疗公司 Organic compound
CA3071119A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment or prophylaxis of central nervous system disorders
US11440911B2 (en) * 2017-09-26 2022-09-13 Intra-Cellular Therapies, Inc. Salts and crystals
MX2020009668A (en) 2018-03-16 2021-01-08 Intra Cellular Therapies Inc Novel methods.
WO2019183341A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
MX2020009929A (en) 2018-03-23 2021-01-08 Intra Cellular Therapies Inc Organic compounds.
JP7568512B2 (en) 2018-05-04 2024-10-16 インサイト・コーポレイション Salt of FGFR inhibitor
CN112384218B (en) 2018-06-06 2024-04-26 细胞内治疗公司 Salt and crystals
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
WO2019241278A1 (en) * 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US11806311B2 (en) 2018-06-21 2023-11-07 Aquestive Therapeutics, Inc. System and method for making personalized individual unit doses containing pharmaceutical actives
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
KR20210052472A (en) * 2018-08-31 2021-05-10 인트라-셀룰라 써래피스, 인코퍼레이티드. New way
CA3108553A1 (en) * 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
EP3846778A1 (en) 2018-09-07 2021-07-14 Aquestive Therapeutics, Inc. Oral film compositions and dosage forms having precise active dissolution profiles
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
AU2019403149B2 (en) 2018-12-17 2025-04-03 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
KR20210104785A (en) 2018-12-17 2021-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. organic compounds
KR20210104834A (en) 2018-12-17 2021-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. Substituted Heterocycle Fusion Gamma-Carboline Synthesis
JP7377871B2 (en) 2018-12-21 2023-11-10 イントラ－セルラー・セラピーズ・インコーポレイテッド organic compound
EP3897621A4 (en) 2018-12-21 2022-09-07 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
CN114072150A (en) 2019-07-07 2022-02-18 细胞内治疗公司 New method
WO2021087359A1 (en) 2019-11-01 2021-05-06 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
WO2021097247A1 (en) 2019-11-14 2021-05-20 Aquestive Therapeutics, Inc. Multimodal compositions and methods of treatment
US11753419B2 (en) 2019-12-11 2023-09-12 Intra-Cellular Therapies, Inc. 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders
CA3208345A1 (en) 2021-01-15 2022-07-21 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
CA3210706A1 (en) 2021-03-09 2022-09-15 Alexander Mark Schobel Dosage forms having equivalent biocomparable profiles
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
US20250195510A1 (en) 2022-05-18 2025-06-19 Intra-Cellular Therapies, Inc. Novel methods
WO2024173901A1 (en) * 2023-02-17 2024-08-22 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US3606908A (en) 1969-11-26 1971-09-21 Trico Products Corp Ventilation system for volatile fluid
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
JPS5014494A (en) * 1973-06-11 1975-02-15
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
IE41352B1 (en) 1974-04-01 1979-12-19 Pfizer 5-aryl-1,2,3,4-tetrahydro- -carbolines
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4522944A (en) 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
SE8304361D0 (en) * 1983-08-10 1983-08-10 Ferrosan Ab NOVEL 1-ACYLPIPERAZINE DERIVATIVES NOVEL 1-ACYLPIPERAZINE DERIVATIVES
CH656884A5 (en) 1983-08-26 1986-07-31 Sandoz Ag POLYOLESTERS, THEIR PRODUCTION AND USE.
JPS6175A (en) * 1984-03-06 1986-01-06 ブリストル−マイア−ズ　コムパニ− Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl) piperazine derivative
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
EP0238059B1 (en) 1986-03-19 1993-06-16 Kumiai Chemical Industry Co., Ltd. 5H-1,3,4-Thiazole[3,2-a]pyrimidin-5-one derivatives and fungicidal compositions containing the same
JP2641443B2 (en) 1986-04-07 1997-08-13 クミアイ化学工業株式会社 5H-1,3,4-thiadiazolo [3,2-a] pyrimidin-5-one derivative and agricultural / horticultural fungicide containing the same as an active ingredient
FI95572C (en) 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
EP0392059B1 (en) 1989-04-14 1993-09-15 Merz & Co. GmbH & Co. Use of adamantane derivatives in the prevention and treatment of cerebral ischemia
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
IT1271352B (en) 1993-04-08 1997-05-27 Boehringer Ingelheim Italia INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
JP3645906B2 (en) 1993-11-19 2005-05-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5648539A (en) 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5654482A (en) 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
US5648542A (en) 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US5723671A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
US6395939B1 (en) 1997-10-06 2002-05-28 Massachusetts Institute Of Technology Diaryl ether condensation reactions
WO1999043643A2 (en) 1998-02-26 1999-09-02 Massachusetts Institute Of Technology Metal-catalyzed arylations and vinylations of hydrazines, hydrazones, hydroxylamines and oximes
US6235936B1 (en) 1998-02-26 2001-05-22 Massachusetts Institute Of Technology Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
US5902901A (en) 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
EP1097158B1 (en) 1998-07-10 2006-01-25 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US20010008942A1 (en) 1998-12-08 2001-07-19 Buchwald Stephen L. Synthesis of aryl ethers
HUP0104721A3 (en) 1998-12-17 2006-07-28 Alza Corp Mountain View Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
AR023574A1 (en) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc TETRACICLIC AZEPININDOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS TO PREPARE A MEDICINAL PRODUCT, AND INTERMEDIARIES
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
ES2223536T3 (en) 1999-06-15 2005-03-01 Bristol-Myers Squibb Pharma Company GAMMA-CARBOLINS CONDENSED WITH REPLACED HETEROCICLES.
US7071186B2 (en) * 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
CA2432185C (en) 2000-12-20 2011-11-08 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
CA2445159C (en) 2001-04-24 2012-09-11 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
DE60206636T2 (en) 2001-08-08 2006-06-22 Pharmacia & Upjohn Co. Llc, Kalamazoo THERAPEUTIC 1H-PYRIDO [4,3-b] INDOLE
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR100699516B1 (en) 2002-07-29 2007-03-26 알자 코포레이션 Methods and dosage forms for the controlled delivery of paliperidone
CA2494404A1 (en) 2002-08-02 2004-02-12 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
US20040142970A1 (en) 2002-11-01 2004-07-22 Kathryn Chung Treatment of hyperkinetic movement disorder with donepezil
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004056324A2 (en) 2002-12-19 2004-07-08 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
SI2009000T1 (en) 2003-01-16 2011-09-30 Acadia Pharm Inc Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
MXPA06000725A (en) 2003-07-21 2006-03-30 Smithkline Beecham Corp (2s, 4s)-4-fluoro -1-[4-fluoro -beta-(4- fluorophenyl)- l-phenylalanyl] -2- pyrrolidinecarbonitrile p- toluenesulfonic acid salt and anhydrous crystalline forms thereof.
JP2005259113A (en) 2004-02-12 2005-09-22 Ricoh Co Ltd Process editing apparatus, process management apparatus, process editing program, process management program, recording medium, process editing method and process management method
WO2005095396A1 (en) 2004-03-05 2005-10-13 Pharma C S.A. 8-phenoxy-ϝ carboline derivatives
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
JP5289765B2 (en) * 2004-09-20 2013-09-11 マウント シナイ スクール オブ メディシン Use of memantine (namenda) for the treatment of autism, obsessive-compulsive disorder, and impulsivity
CA2581023A1 (en) 2004-09-21 2006-03-30 Pfizer Products Inc. N-methyl hydroxyethylamine useful in treating cns conditions
DE602005019465D1 (en) 2004-12-15 2010-04-01 Hoffmann La Roche BI- AND TRICYCLIC SUBSTITUTED PHENYL-METHANONE AS INHIBITORS OF GLYCIN-I (GLYT-1) TRANSPORTERS FOR THE TREATMENT OF ALZHEIMER DISEASE
JP5084725B2 (en) * 2005-06-06 2012-11-28 武田薬品工業株式会社 Organic compounds
KR102065319B1 (en) 2007-03-12 2020-01-10 인트라-셀룰라 써래피스, 인코퍼레이티드. Substituted heterocycle fused gamma-carbolines synthesis
WO2009017836A1 (en) 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
NZ586963A (en) * 2008-02-05 2012-11-30 Clera Inc Use of dopamine d2 receptor inhibitors for alleviating depression or improving cognition
MX347257B (en) 2008-03-12 2017-04-20 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines solid.
CN102105059B (en) 2008-05-27 2015-09-30 细胞内治疗公司 Methods and compositions for sleep disorders and other disorders
KR101868165B1 (en) 2010-04-22 2018-07-19 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
WO2013155504A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel methods
US10011602B2 (en) 2012-07-06 2018-07-03 The University Of Melbourne Immunological reagents and uses therefor
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
US9161061B2 (en) 2013-03-15 2015-10-13 Pictech Management Limited Data storage and exchange device for color space encoded images
CN105939712A (en) 2013-12-03 2016-09-14 细胞内治疗公司 new method
KR20170012210A (en) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
KR20240170975A (en) 2016-01-26 2024-12-05 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
ES2879888T3 (en) 2016-03-25 2021-11-23 Intra Cellular Therapies Inc Organic compounds and their use in the treatment or prevention of disorders of the central nervous system
EP3436455A4 (en) 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
IL268970B2 (en) 2017-03-24 2023-12-01 Intra Cellular Therapies Inc Oral transmucosal formulations of substituted heterocycle fused gamma carbolines
CN111093664B (en) 2017-07-26 2023-06-02 细胞内治疗公司 Organic compound
CA3071119A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment or prophylaxis of central nervous system disorders

Also Published As

Publication number Publication date
US20150079172A1 (en) 2015-03-19
EP2836213A1 (en) 2015-02-18
EP2836211A4 (en) 2015-09-09
WO2013155505A1 (en) 2013-10-17
CA2870303A1 (en) 2013-10-17
MX2014012374A (en) 2015-04-17
JP2015516395A (en) 2015-06-11
US20200017499A1 (en) 2020-01-16
US11053245B2 (en) 2021-07-06
US20150080404A1 (en) 2015-03-19
JP2015514135A (en) 2015-05-18
JP2018168161A (en) 2018-11-01
US20210002280A1 (en) 2021-01-07
US11958852B2 (en) 2024-04-16
HK1206630A1 (en) 2016-01-15
WO2013155506A1 (en) 2013-10-17
US20210371421A1 (en) 2021-12-02
ES2727815T3 (en) 2019-10-18
JP6242855B2 (en) 2017-12-06
EP2836213B1 (en) 2018-07-04
EP2836211A1 (en) 2015-02-18
RU2014145682A (en) 2016-06-10
US9428506B2 (en) 2016-08-30
US11124514B2 (en) 2021-09-21
US20200407362A1 (en) 2020-12-31
EP3791879A1 (en) 2021-03-17
AU2013245702A1 (en) 2014-11-13
JP2015512951A (en) 2015-04-30
US20150072964A1 (en) 2015-03-12
EP2836212A1 (en) 2015-02-18
CN104519886B (en) 2017-09-12
EP2836212A4 (en) 2015-09-09
EP2836213A4 (en) 2015-09-09
EP2836211B1 (en) 2019-03-20
CN104519886A (en) 2015-04-15
JP2023159345A (en) 2023-10-31
US20240208974A1 (en) 2024-06-27
WO2013155504A1 (en) 2013-10-17
KR20140146192A (en) 2014-12-24
JP2021098724A (en) 2021-07-01
JP6334511B2 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
IN2014DN08562A (en)
MX2021013564A (en) Organic compounds.
MX339805B (en) Organic compounds.
MX2021010306A (en) GAMMA-SUBSTITUTED FUSED HETEROCYCLIC CARBOLINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE.
MX365969B (en) Organic compounds.
MX2016013046A (en) Organic compounds.
MX2020000968A (en) Organic compounds.
MX2020000967A (en) Organic compounds.
MX2021000550A (en) Tofacitinib oral sustained release dosage forms.
MX2021011906A (en) Delayed release compositions of linaclotide.
MX2020009929A (en) Organic compounds.
MX348823B (en) Stable formulations of linaclotide.
MX2021007217A (en) Organic compound.
IN2015DN03921A (en)
UA118562C2 (en) Cxcr7 receptor modulators
MX2015007945A (en) Uses and methods for the treatment of liver diseases or conditions.
MY189372A (en) Indole derivatives
TN2016000557A1 (en) Pharmaceutical dosage forms
GR1008169B (en) Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof
GB2569616B (en) Sustained release oral pharmaceutical compositions of dicycloverine
HK1220615A1 (en) Organic compounds
IN2013MU03838A (en)
GR1008082B (en) Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
IN2013MU01239A (en)
IN2013MU01944A (en)